Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners